A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1b/2a Study to Evaluate the Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
In the register
The register attaches this trial to OLX104C (OLX72021) (Olix Pharmaceuticals), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 1/2
- Sponsor
- Olix Pharmaceuticals, Inc.
- Participants (registry)
- 158
- Start
- December 2025
- Primary completion
- April 2026
- Study completion
- March 2027 (planned)
- Last registry update
- March 2026
- Countries
- Australia
Conditions studied: Androgenetic Alopecia (AGA)
Interventions: OLX72021, OLX72021, OLX72021, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.